Resources - MECHANISMS
Tirzepatide dosage, how it is taken and side effects: what the trials and the UK licence say
Tirzepatide (Mounjaro) is a licensed weekly injection in the UK. The doses the licence sets, how the dose is stepped up, the weight and blood-sugar results from the trials, the side effects recorded, how NHS access works, and why the licensed route matters.
Tirzepatide, sold in the UK as Mounjaro, is a once-weekly injection licensed for type 2 diabetes and for weight management. The dose is not a single number: treatment starts at 2.5 mg a week and is increased in 2.5 mg steps, no faster than every four weeks, to a maintenance dose of 5 mg, 10 mg or 15 mg chosen by the prescriber. In the largest weight trial, people on those maintenance doses lost on average between 15% and 21% of their body weight over 72 weeks, with stomach and gut side effects the main reason people struggled. This article explains where those figures come from, how the drug is taken, what the side-effect data show, and how the licensed route works in the UK. It is an explanation of a licensed medicine, not a recommendation to take it; the person who can decide whether it suits you is a prescriber.
What tirzepatide is and why it is different from semaglutide
Tirzepatide is a single molecule that activates two receptors involved in appetite and blood-sugar control: the GLP-1 receptor, which semaglutide also targets, and the GIP receptor, which semaglutide does not. Both hormones are released from the gut after eating and signal to the pancreas and brain. Activating both appears to produce a larger effect on weight than GLP-1 alone, which is why tirzepatide's trial results sit above semaglutide's. It was developed by Eli Lilly, licensed for type 2 diabetes first, and later for weight management in adults with obesity, or overweight plus a weight-related condition, alongside a reduced-calorie diet and increased physical activity.
The licensed tirzepatide dosing schedule
The UK product information sets out a fixed way of starting and increasing the dose, and it is the same for diabetes and weight management.
- Start at 2.5 mg once weekly for four weeks. This dose is for getting the body used to the drug; it is not intended as a long-term maintenance dose.
- Increase to 5 mg once weekly. This is the lowest maintenance dose.
- If more effect is needed and the current dose is tolerated, increase in further 2.5 mg steps (7.5 mg, 10 mg, 12.5 mg) after at least four weeks at each step.
- The maximum dose is 15 mg once weekly. Maintenance is at 5 mg, 10 mg or 15 mg, chosen by the prescriber according to response and tolerability.
Two features of the schedule explain a lot of what people read online. First, the slow start is deliberate: the gut side effects are dose-related and are worst when the dose rises, so stepping up slowly keeps them manageable. In the trials, faster escalation was associated with more gastrointestinal side effects and more discontinuations, which is why the licence fixes the minimum interval at four weeks. Second, the dose is a fixed amount for everyone, not adjusted for body weight, and the prescriber decides where to settle. A heavier person is not automatically on a higher dose; the dose is set by response and side effects, reviewed at each step.
How tirzepatide is taken
The licence describes administration as once a week, on the same day each week, by injection into the fatty tissue under the skin of the abdomen, thigh or the back of the upper arm, rotating the site. In the UK it is supplied as a pre-filled pen at each licensed strength; the KwikPen version holds four weekly doses and the dose is dialled before each injection. It can be taken at any time of day, with or without food. A pharmacist or clinician demonstrates the pen at the start and the patient is reviewed as the dose changes.
The licensed information also covers the practicalities that generate a lot of search traffic. A missed dose can be taken within four days; beyond that it is skipped and the next taken as normal. The pen is kept in a fridge before first use and can be kept at room temperature, below 30°C, for a limited period once in use. The licence does not address alcohol; the NHS advises avoiding it while on tirzepatide because it can worsen nausea and vomiting. None of these details is a substitute for the patient leaflet, which comes with the medicine and is written for exactly these questions.
Weight loss in the trials, by dose
The trial behind the weight-management licence is SURMOUNT-1, published in the New England Journal of Medicine in 2022. It enrolled 2,539 adults with a body-mass index of 30 or more, or 27 or more with at least one weight-related condition, and excluded people with diabetes. Participants were randomised to placebo or to tirzepatide at 5 mg, 10 mg or 15 mg weekly, reached by the standard escalation, and followed for 72 weeks alongside lifestyle support.
At 72 weeks the average change in body weight was about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, compared with about 3.1% on placebo. Around nine in ten participants on tirzepatide lost at least 5% of their body weight, and more than half of those on 15 mg lost 20% or more. Later trials in the same programme studied people with diabetes, people who had already lost weight through lifestyle change, and what happens when the drug is stopped: weight tends to return, which is why it is licensed as an ongoing treatment rather than a course.
These are averages from a monitored trial with dietary and activity support, and they should be read as such. Individual responses ranged widely in both directions, some people stopped because of side effects, and the trial population was selected. That is the honest frame for any weight-loss number you see quoted for this drug.
Side effects recorded in the trials and on the licence
The dominant side effects are gastrointestinal: nausea, diarrhoea, constipation, vomiting, indigestion and reduced appetite. In SURMOUNT-1 they were mostly mild to moderate, they were most frequent during dose escalation, and they were more common at higher doses. A minority of participants stopped treatment because of them, more at 15 mg than at 5 mg.
The licence lists less common but more serious risks: acute pancreatitis; gallbladder disease including gallstones; low blood sugar when taken with insulin or a sulfonylurea; and severe gastrointestinal effects that can lead to dehydration and kidney problems. Because the drug slows stomach emptying, it can change how other oral medicines are absorbed, and women using oral contraceptives are advised to use an additional method for a period after starting or increasing the dose. Separately from the licence, rapid weight loss itself carries risks, including for people with an eating disorder history. These are the reasons the drug is prescribed and monitored rather than sold.
How access works in the UK
Tirzepatide is a prescription-only medicine. For type 2 diabetes it has been prescribable for several years. For weight management, NICE recommended it in December 2024, and NHS England began a phased rollout in mid-2025, starting with people at the highest body-mass index who also have several weight-related conditions and widening in stages over subsequent years. Eligibility is assessed by a GP or a specialist weight-management service, and treatment comes with the diet, activity and monitoring that the trials also included. Outside the NHS, tirzepatide can only be supplied against a prescription issued after a clinical assessment.
What is not lawful is buying tirzepatide without a prescription, or a seller advertising it to the public. Anything sold online as "research grade" tirzepatide, or as a filled pen from an unknown source, is an unlicensed product: no regulator has checked what it contains, how much is in it, or whether it is sterile. The trial figures above describe the licensed medicine at a known dose; they say nothing about a vial of unknown content. The MHRA has seized such products and made arrests under the Human Medicines Regulations 2012.
Why the licensed dosing schedule is the whole point
A licensed dose is the end product of a long chain: trials that found the range, a regulator that reviewed them and approved specific strengths, a manufacturer that guarantees each pen contains what it says, and a prescriber who chooses within the range for one person and adjusts as they go. Tirzepatide has the complete chain. That is what separates it from compounds that are still in trials, where only the first link exists, and from unlicensed copies, where none of the links can be trusted.
It also means the question "what tirzepatide dose should I take" has a real answer, and the answer is whatever a prescriber sets for a particular patient after assessment, starting at 2.5 mg and reviewing at each step. That is not evasion. It is the difference between a medicine and a number.
How to read a tirzepatide claim
- Check whether the figure comes from a published trial, and which one: the diabetes trials, the obesity trials and the stopping trial answer different questions.
- Check the dose and the duration together. A 72-week result at 15 mg after a slow escalation is not a 12-week result.
- Check whether side effects are reported alongside the benefit. Balanced sources report both.
- Check whether the source is selling something. A page describing the licensed medicine has no reason to sell you a vial.
This article is educational content only and is not medical advice, diagnosis or a recommendation to use any medicine. Tirzepatide is a prescription-only medicine; the doses described are those set by its UK licence and used in monitored clinical trials, and they are not instructions for use. Anyone considering treatment for weight or blood sugar should speak to a GP, pharmacist or other qualified prescriber. Vivera Education sells nothing.
Frequently asked
- What is the tirzepatide dose?
- The UK licence for tirzepatide (Mounjaro) starts at 2.5 mg once a week for four weeks, then increases in 2.5 mg steps at intervals of at least four weeks to a maintenance dose of 5 mg, 10 mg or 15 mg weekly, chosen and adjusted by the prescriber. The 2.5 mg dose is for starting, not for maintenance.
- How is tirzepatide taken?
- As a once-weekly injection under the skin of the abdomen, thigh or upper arm, using the licensed pre-filled pen, on the same day each week, with or without food. Patients are shown how to use the pen by a pharmacist or clinician and are reviewed as the dose is increased.
- How much weight do people lose on tirzepatide?
- In the 72-week SURMOUNT-1 trial of 2,539 adults with obesity but not diabetes, average weight change was about 15% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against about 3.1% on placebo. Individual results varied widely, and the trial included diet and activity support alongside the drug.
- What are the side effects of tirzepatide?
- Most commonly nausea, diarrhoea, constipation, vomiting and reduced appetite, generally mild to moderate and most frequent during dose increases. Less common effects include gallbladder problems and, in people also taking insulin or sulfonylureas, low blood sugar. Pancreatitis is a rare but serious risk. The licensed patient leaflet lists the full profile.
- Is tirzepatide available on the NHS?
- Yes, in stages. NICE recommended it for weight management in December 2024 with a phased rollout from mid-2025 that prioritises people with the highest body-mass index and most weight-related conditions; it is also prescribed for type 2 diabetes. GPs and specialist weight services can advise on eligibility. Outside the NHS it can only be supplied against a prescription issued after a clinical assessment.
- Can I buy tirzepatide without a prescription in the UK?
- No. Tirzepatide is a prescription-only medicine. It cannot lawfully be sold to the public without a prescription, and it cannot be advertised to the public. Products sold online as "research" tirzepatide are unlicensed and have not been checked by any regulator for identity, dose or sterility.
- What happens if a dose is missed?
- The licensed information allows a missed dose to be taken within four days of when it was due; after that the dose is skipped and the next one taken on the usual day. This is a summary of the product information, not personal advice; a pharmacist or prescriber can advise on an individual situation.
- Does tirzepatide work for people without diabetes?
- The SURMOUNT-1 trial studied adults with obesity or overweight and a weight-related condition, without diabetes, and found substantial average weight loss at every dose. That is the basis of its UK licence for weight management, alongside its earlier licence for type 2 diabetes.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.